Urologix Analysis
ULGXDelisted Stock | USD 0.0001 0.00 0.00% |
Urologix is overvalued with Real Value of 8.5E-5 and Hype Value of 1.0E-4. The main objective of Urologix pink sheet analysis is to determine its intrinsic value, which is an estimate of what Urologix is worth, separate from its market price. There are two main types of Urologix's stock analysis: fundamental analysis and technical analysis.
The Urologix pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Urologix |
Urologix Pink Sheet Analysis Notes
The company recorded a loss per share of 0.22. Urologix had not issued any dividends in recent years. Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota. UROLOGIX operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 61 people.The quote for Urologix is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more information please call Bryon Merade at 763 475 1400 or visit https://www.urologix.com.Urologix Investment Alerts
Urologix is not yet fully synchronised with the market data | |
Urologix has some characteristics of a very speculative penny stock | |
Urologix has a very high chance of going through financial distress in the upcoming years | |
Urologix currently holds 4.59 M in liabilities. Urologix has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Urologix until it has trouble settling it off, either with new capital or with free cash flow. So, Urologix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Urologix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Urologix to invest in growth at high rates of return. When we think about Urologix's use of debt, we should always consider it together with cash and equity. | |
The entity reported the previous year's revenue of 14.01 M. Net Loss for the year was (7.61 M) with profit before overhead, payroll, taxes, and interest of 5.9 M. | |
Urologix currently holds about 492 K in cash with (1.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Urologix Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 82.91 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Urologix's market, we take the total number of its shares issued and multiply it by Urologix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Urologix Profitablity
The company has Profit Margin (PM) of (0.39) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07.Urologix Outstanding Bonds
Urologix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Urologix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Urologix bonds can be classified according to their maturity, which is the date when Urologix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
International Game Technology Corp BondUS460599AD57 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View |
About Urologix Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Urologix prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Urologix shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Urologix. By using and applying Urologix Pink Sheet analysis, traders can create a robust methodology for identifying Urologix entry and exit points for their positions.
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota. UROLOGIX operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 61 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Urologix to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stock Tickers Now
Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Urologix Pink Sheet
If you are still planning to invest in Urologix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Urologix's history and understand the potential risks before investing.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |